![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 305, Issue 1, 78-85, April 2003
Department of Molecular and Cellular Physiology (M.S., A.W., H.H,
P.C., J.W.E., M.B.G., J.S.A.), Microbiology and Immunology (M.W.),
Gastroenterology (P.J., K.M.), and Pathology (S.B.), Louisiana State
University Health Sciences Center, Shreveport, Louisiana; and
Department of Internal Medicine and Bioregulation (T.J.), Nagoya City
University Graduate School of Medical Sciences, Nagoya, Japan
The dextran sulfate (DSS) model of colitis causes intestinal injury
sharing many characteristics with inflammatory bowel disease, e.g.,
leukocyte infiltration, loss of gut epithelial barrier, and cachexia.
These symptoms are partly mediated by entrapped leukocytes binding to
multiple endothelial adhesion molecules (MAdCAM-1, VCAM-1, ICAM-1, and
E-selectin). Pravastatin, an 3-hydroxy-3-methylglutaryl (HMG)-CoA
reductase inhibitor, has anti-inflammatory potency in certain
inflammation models; therefore, in this study, we measured the effects
of pravastatin in DSS-induced colitis. The administration of
pravastatin (1 mg/kg) relieved DSS-induced cachexia, hematochezia, and
intestinal epithelial permeability, with no effect on serum cholesterol. Histopathologically, pravastatin prevented leukocyte infiltration and gut injury. Pravastatin also blocked the mucosal expression of MAdCAM-1. DSS treatment promoted mucosal endothelial nitric-oxide synthase (eNOS) mRNA degradation, an effect that was
blocked by pravastatin. Importantly, the protective effects of
pravastatin in DSS-induced colitis were not found in eNOS-deficient mice. Our results demonstrate that HMG-CoA reductase inhibitors preserve intestinal integrity in colitis, most likely via increased eNOS expression and activity, independent of cholesterol metabolism.